Neurogene Inc. Restructuring Reserve
Neurogene Inc. (NGNE) had Restructuring Reserve of $900.00 thousand as of 2023-12-18, per its 10-K filed 2024-03-18.
Discontinued › Balance Sheet › Liabilities
us-gaap:RestructuringReserve · last filed 2024-03-18
- 2023-12-18: Restructuring Reserve $900.00K.
- 2023-09-30: Restructuring Reserve $458.00K.
- 2023-06-30: Restructuring Reserve $874.00K.
- 2023-03-31: Restructuring Reserve $2.17M.
| Period end | Restructuring Reserve |
|---|---|
| 2023-12-18 | $900.00K 10-K · filed 2024-03-18 |
| 2023-09-30 | $458.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $874.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $2.17M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.04M 10-Q · filed 2023-11-14 |
| 2018-09-30 | $5.63M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |